Method of identifying disease risk factors
Provided herein is a method for identifying a genetic variant that is associated with development of a condition of interest (e.g., Alzheimer's disease), and genetic variants so identified. Methods of treatment with an active agent (e.g., with a particular active agent and/or at an earlier age) is also provided, upon detecting a genetic variant described herein. In some embodiments, the genetic variant is a deletion/insertion polymorphism (DIP) of the TOMM40 gene. Kits for determining if a subject is at increased risk of developing late onset Alzheimer's disease is also provided. Kits for determining if a subject is responsive to treatment for a condition of interest with an active agent are further provided.
1. A method of determining increased risk for development of Alzheimer's disease in a human subject, comprising:
(a) detecting the length of a poly-T deletion/insertion polymorphism (DIP) at rs10524523 in intron 6 of the TOMM40 gene from a biological sample containing DNA taken from said subject, wherein said poly-T DIP has a length of 21, 22, 23, 26, 27, 28, 29, or 30;
(b) correlating the detected poly-T length of 21, 22, 23, 26, 27, 28, 29, or 30 at rs10524523 with an increased risk of development of Alzheimer's disease; and
(c) administering an anti-Alzheimer's disease active agent to said subject in an amount effective for treating said subject.
2. The method of claim 1 , further comprising detecting an ApoE genotype of E2/E2, E2/E3, E2/E4, E3/E3, E3/E4, or E4/E4 in said subject.
3. The method of claim 2 , comprising detecting the Apo E3/E3 or E3/E4 genotype in said subject.
4. The method of claim 1 , wherein said administering is carried out in said subject at an earlier age compared to a subject that does not have an rs10524523 allele with a poly-T length of 21, 22, 23, 26, 27, 28, 29, or 30.
5. The method of claim 1 wherein said active agent is selected from the group consisting of acetylcholinesterase inhibitors, NMDA receptor antagonists, peroxisome proliferator-activated receptor agonists or modulators, antibodies, fusion proteins, therapeutic RNA molecules, and combinations thereof.
6. A method of treating a non-symptomatic human subject at increased risk of developing Alzheimer's disease comprising:
(a) detecting the length of a poly-T deletion/insertion polymorphism (DIP) at rs10524523 in intron 6 of the TOMM40 gene from a biological sample containing DNA taken from said subject, wherein said poly-T DIP has a length of 21, 22, 23, 26, 27, 28, 29, or 30; and
(b) administering an anti-Alzheimer's disease active agent to said subject in an amount effective for treating said subject.
7. The method of claim 6 , further comprising detecting an ApoE genotype of E2/E2, E2/E3, E2/E4, E3/E3, E3/E4, or E4/E4 in said subject.
8. The method of claim 7 , comprising detecting the Apo E3/E3 or E3/E4 genotype in said subject.
9. The method of claim 6 wherein said active agent is selected from the group consisting of acetylcholinesterase inhibitors, NMDA receptor antagonists, peroxisome proliferator-activated receptor agonists or modulators, antibodies, fusion proteins, therapeutic RNA molecules, and combinations thereof.
10. A method of determining the risk for developing Alzheimer's disease in a patient comprising:
(i) obtaining a patient profile, comprising:
detecting the presence or absence of at least one ApoE 2, ApoE 3, or ApoE 4 allele in a biological sample of said patient, and
detecting the length of a poly-T deletion/insertion polymorphism (DIP) at rs10524523 in intron 6 of the TOMM40 gene from a biological sample containing DNA taken from said patient, wherein said poly-T DIP has a length of 21, 22, 23, 26, 27, 28, 29, or 30;
(ii) determining that said patient is at an increased risk for developing Alzheimer's disease; and
(iii) administering an anti-Alzheimer's disease active agent to said patient in an amount effective for treating said patient.
11. The method claim 10 , further comprising detecting an ApoE genotype of E2/E2, E2/E3, E2/E4, E3/E3, E3/E4, or E4/E4 in said patient.
12. The method of claim 1 , wherein said active agent is a thiazolidinedione.
13. The method of claim 12 , wherein said thiazolidinedione is formulated in a pharmaceutical carrier.
14. The method of claim 6 , wherein said active agent is a thiazolidinedione.
15. The method of claim 14 , wherein said thiazolidinedione is formulated in a pharmaceutical carrier.
16. The method of claim 1 , wherein said treating comprises delaying the onset of Alzheimer's disease.
17. The method of claim 6 , wherein said treating comprises delaying the onset of Alzheimer's disease.
18. A method of delaying the onset of Alzheimer's disease in a non-symptomatic human subject, comprising:
a) detecting the length of a poly-T deletion/insertion polymorphism (DIP) at rs10524523 in intron 6 of the TOMM40 gene from a biological sample containing DNA taken from said subject, wherein said poly-T DIP has a length of 21, 22, 23, 26, 27, 28, 29, or 30; and
b) administering an active agent to said subject in an amount effective to delay the onset of Alzheimer's disease.
19. The method of claim 1 , wherein said detecting the poly-T deletion/insertion polymorphism (DIP) at rs10524523 comprises PCR amplification and/or DNA sequencing.
20. The method of claim 10 , wherein said detecting the poly-T deletion/insertion polymorphism (DIP) at rs10524523 comprises PCR amplification and/or DNA sequencing.
21. The method of claim 1 , wherein said active agent is a peroxisome proliferator-activated receptor agonist or modulator.
22. The method of claim 6 , wherein said active agent is a peroxisome proliferator-activated receptor agonist or modulator.